Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 春立医疗 |
|---|---|
| Other Market Stock Code | 688236 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Chunli Medical |
|---|---|
| Stock Code | 01858 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一間專注於研發、生產及銷售植入性骨科醫療器械且信譽良好的中國骨科醫療器械公司,產品包括關節假體產品及脊柱產品。我們的關節假體產品包括髖關節假體、膝關節假體、肩關節假體及肘關節假體產品。我們的脊柱產品為脊柱內固定系統的全系列產品組合,包括頸椎前後路固定系統、胸椎固定系統及腰椎固定系統。 |
| Listing Date | 2015-03-11 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市通州區通州經濟開發區南區鑫覓西二路10號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.clzd.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 13.88 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2015-02-27 to 2015-03-04 |
| Global Offering Shares | 16,670,000 shares |
| HK Public Offer Shares (Initial) | 1,667,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 15,003,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 66,670,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 231,379,600 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 953M |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣32.7百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2011 | 2012 | 2013-09 | 2013 | 2014-09 |
|---|---|---|---|---|---|
| Revenue | 80,260 | 98,095 | 72,652 | 110,546 | 91,346 |
| Cost of sales | -19,747 | -27,536 | -20,998 | -30,471 | -24,441 |
| Gross profit | 60,513 | 70,559 | 51,654 | 80,075 | 66,905 |
| Selling and distribution expenses | -13,022 | -16,344 | -14,878 | -20,145 | -19,341 |
| Administrative expenses | -11,316 | -16,131 | -14,034 | -20,581 | -19,273 |
| Operating profit | 34,717 | 35,968 | 20,438 | 37,709 | 25,785 |
| Profit before tax | 35,410 | 37,203 | 20,847 | 38,116 | 26,138 |
| Income tax expense | -5,005 | -5,263 | -2,955 | -5,451 | -3,469 |
| Profit for the year | 30,405 | 31,940 | 17,892 | 32,665 | 22,669 |
Balance Sheet
| Item | 2011 | 2012 | 2013 | 2014-09 | 2015-01 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 44,730 | 61,258 | 65,856 | 46,828 | 49,787 |
| Trade and bills receivables | 23,958 | 30,654 | 33,653 | 54,260 | 52,119 |
| Inventories | 17,775 | 19,587 | 23,081 | 30,530 | 38,199 |
| Total current assets | 96,618 | 120,663 | 132,704 | 145,309 | 162,269 |
| Total assets | 158,764 | 187,510 | 200,633 | 218,181 | 239,739 |
| Total current liabilities | 11,480 | 14,340 | 15,070 | 18,967 | 22,524 |
| Total liabilities | 11,480 | 20,286 | 20,744 | 26,623 | 30,111 |
| Total equity | 147,284 | 167,224 | 179,889 | 191,558 | 209,628 |
Cash Flow Statement
| Item | 2011 | 2012 | 2013-09 | 2013 | 2014-09 |
|---|---|---|---|---|---|
| Net cash from operating activities | 32,463 | 28,828 | -11,266 | 28,202 | 304 |
| Net cash from investing activities | -47,594 | -299 | -13,125 | -1,241 | -4,042 |
| Net cash from financing activities | -2,000 | -12,000 | -2,364 | -22,364 | -15,290 |
| Net increase in cash | -17,131 | 16,529 | -26,755 | 4,597 | -19,028 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 14.3 |
|---|---|
| First Day Open | HK$ 14.08 |
| First Day Change | 3.03% |
| First Day Volume | 10167800.0 |
| First Day Turnover | 148959000.0 |
| Use of Proceeds | 1、全球發售所得款項凈額約50.0%或約97.5百萬港元將用于發展大興新生產基地第一期,包括:
1、1 約20.0%或約39百萬港元用作興建新生產廠房及配套設施;
1、2 約30.0%或約58.5百萬港元用作就標準關節假體、先進個性化關節假體及脊柱產品之生產而購置及安裝生產設備及機器。當新生產線開始運作(目前預計將為2017年10月前后),我們的標準假體、先進個性化關節假體及脊柱產品最大設計年產能將分別增加約40,000套、5,000套及25,000套;
2、全球發售所得款項凈額約20.2%或約39.39百萬港元將用于研發活動,包括:
2、1 約12.0%或約23.4百萬港元用作發展大興新生產基地之研發中心;
2、2 約4.2%或約8.19百萬港元用作購置新的研發設施及設備;
2、3 約4.0%或7.8百萬港元用作擴大我們就開發新產品及改善產品之研發活動之范疇;
3、全球發售所得款項凈額約20.0%或約39百萬港元將用于擴闊我們的現有營銷及經銷網絡以提升我們的市場滲透范圍至涵蓋更多經銷商及醫院,并因而增加我們的市場份額,包括:
3、1 約8.5%或約16.575百萬港元用作于大興新生產基地及中國其他地區建立及發展營銷服務中心,以擴闊我們營銷服務的地域覆蓋范圍;
3、2 約6.0%或11.7百萬港元用作招聘負責營銷之員工,以鞏固我們與醫院及醫療機構之關系及加強醫療執業人員對我們產品的認識;
3、3 約5.5%或10.725百萬港元用作贊助并參與學術會議及研討會;
4、全球發售所得款項凈額約9.8%或約19.11百萬港元將用于營運資金及其他一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
CHINA EVERBRIGHT CAPITAL LIMITED CE ACE409
Overall Coordinators (1)
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Joint Bookrunners (1)
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Joint Lead Managers (1)
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 史春寶 | — |
| Company Secretary | 丁罡、葉沛森 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 史春寶先生及岳術俊女士為控股股東,截至最後實際可行日期分別持有24,237,087股及18,762,913股內資股,佔已發行股本約48.5%及37.6%;緊隨全球發售完成後(假設超額配股權未獲行使)分別持有約36.4%及28.1%,合共約64.5%。 |
|---|




